EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology and Gilead Sciences Forge $1.88 Billion Collaboration for Solid Tumor Cancer Therapies, ETPharma
Stock Market Movers: Best and Worst Performers of 14 October 2026
Gilead Sciences (NASDAQ:GILD) Stock Price Up 3.9% - What's Next?
Vir partners with Gilead in $1.8B+ deal for T-cell engagers
Verastem focuses on KRAS G12D therapy, reports 41% ORR in PDAC
Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs
Vir Biotechnology Shares Jump on Gilead Cancer Collaboration | Morningstar
Vir CEO sees 'opportunity to do more deals' after striking $1.9B Gilead pact for dual-masked TCEs
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC
Promising Pharmaceutical Stocks To Follow Now - October 11th - Markets Daily
Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co. - Daily Political
Fagan Associates Inc. Buys New Stake in Gilead Sciences, Inc. $GILD
Erste Group Bank Comments on Gilead Sciences FY2027 Earnings
44,466 Gilead Sciences, Inc. $GILD Shares Sold by CoreCap Advisors LLC
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biotech Stocks To Watch Today - October 11th - Daily Political
Can Gilead (GILD) Stock Continue Rising in 2027?
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Promising Pharmaceutical Stocks To Follow Now - October 11th - Daily Political
Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?
Top Biotech Stocks To Watch Now - October 10th - Markets Daily
Medical Stocks To Follow Now - October 10th - Daily Political
Gilead Sciences (GILD) Could Be Trading At A 18% Premium Following Strong Earnings
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00 - Daily Political
Medical Stocks To Research - October 9th - Stock Observer
What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?
Gilead Sciences' (GILD) Overweight Rating Reaffirmed at Cantor Fitzgerald - Stock Observer
Gilead Sciences (NASDAQ:GILD) Given Overweight Rating at Cantor Fitzgerald - Stock Observer
Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - Stock Observer
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Daily Political
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says
Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co.
GILD Maintained by Morgan Stanley -- Price Target Lowered to $16
Morgan Stanley Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $163.00
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - Stock Observer
Nurix Extends Gilead Oncology Research Collaboration For Two Years
Zacks Research Lowers Earnings Estimates for Gilead Sciences
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan - Zolmax
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages
31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional
Biotech Stocks To Watch Now - October 2nd - Daily Political
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock
Biotech Stocks To Watch Now - October 2nd - Zolmax
Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 15,000 Shares - Daily Political
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD
HIV prevention drug hailed as breakthrough, but who gets access?
Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research
Zacks Research Downgrades Gilead Sciences (NASDAQ:GILD) to Hold - Stock Observer
GILD: HIV Growth Still Leads, Oncology And Immunology Now Carry More Weight
Vascular Dementia Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 - DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare | ABNewswire
Best Medical Stocks To Watch Today - September 29th - Markets Daily
Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political
Can Lenacapavir Power Gilead Sciences (GILD)'s Next Growth Phase?
Promising Pharmaceutical Stocks To Research - September 28th - Zolmax
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?
A human single-cell atlas identifies OLR1 + scar-associated macrophages as a potential therapeutic target for chronic liver disease
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
Gilead's HIV Concentration or Pfizer's Patent Cliff: Which Risk is Easier to Own?
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts
Reviewing Gilead Sciences (NASDAQ:GILD) & Protalix BioTherapeutics (NYSE:PLX) - Stock Observer
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.
FY2026 EPS Estimate for Gilead Sciences Boosted by Analyst - Daily Political
Biotech Stocks To Follow Now - September 23rd - Stock Observer
Medical Stocks To Watch Today - September 22nd - Stock Observer
FY2027 EPS Forecast for Gilead Sciences Boosted by Analyst - Daily Political
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
State Street Corp Raises Position in Gilead Sciences, Inc. $GILD
Gilead Sciences FY2026 EPS Increased by Erste Group Bank
Biotech Stocks To Consider - September 19th - Zolmax
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Drugmakers move closer to launch landmark HIV drug as CDSCO eases approval process
Biotech Stocks To Watch Now - September 21st - Daily Political
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
GILD: HIV Prevention Promise Faces A Harder Test, Growth Still Looks Thin
Erste Group Bank Estimates Gilead Sciences FY2027 Earnings
Why Morgan Stanley likes Gilead's HIV prevention play
Gilead Sciences (NASDAQ:GILD) Rating Increased to Buy at Wall Street Zen
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Wall Street Zen
Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $435,870.00 in Stock - Daily Political
Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
Top Medical Stocks To Watch Today - September 18th - Daily Political
Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILD
Top Medical Stocks To Keep An Eye On - September 17th - Stock Observer
Dr Reddy's inks licensing deal with Gilead for once-yearly HIV lenacapavir
Biotech Stocks To Keep An Eye On - September 17th - Stock Observer
Dr Reddy's Labs Secures License for Gilead's Revolutionary Once-Yearly HIV Prevention Drug, ETPharma
Gilead News
Is Oracle a Good Buy Right Now? Growth, Valuation and Long-Term Risks
Gold Price Forecast Today and Next 30 Days: Can XAU/USD Extend Its Weekly Rebound?
ASML Stock Forecast 2026–2030: Can It Reach a $1 Trillion Valuation?
Latest news
Show more
Gold Price Today: XAU/USD Rebounds Toward $4,150 After US Inflation Selloff
US PPI and Retail Sales Today: Can Fresh Inflation Data Revive an October Fed Rate Hike?
US CPI Rises to 3.7% as Fed Rate-Hike Bets Send the Nasdaq Down 1.9%
South Korea Chip Stocks Slide as AI Concerns and Export Restrictions Weigh
